Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the US Neuroendocrine Tumor Study Group Merath, K., Bagante, F., Beal, E. W., Lopez-Aguiar, A. G., Poultsides, G., Makris, E., Rocha, F., Kanji, Z., Weber, S., Fisher, A., Fields, R., Krasnick, B. A., Idrees, K., Smith, P. M., Cho, C., Beems, M., Schmidt, C. R., Dillhoff, M., Maithel, S. K., Pawlik, T. M. WILEY. 2018: 868–78

Abstract

The risk of recurrence after resection of non-metastatic gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) is poorly defined. We developed/validated a nomogram to predict risk of recurrence after curative-intent resection.A training set to develop the nomogram and test set for validation were identified. The predictive ability of the nomogram was assessed using c-indices.Among 1477 patients, 673 (46%) were included in the training set and 804 (54%) in y the test set. On multivariable analysis, Ki-67, tumor size, nodal status, and invasion of adjacent organs were independent predictors of DFS. The risk of death increased by 8% for each percentage increase in the Ki-67 index (HR 1.08, 95% CI, 1.05-1.10; P?3 positive nodes had a HR of 1.81 (95% CI, 1.12-2.87; P?=?0.014) and 2.51 (95% CI, 1.50-4.24; P?

View details for PubMedID 29448303

View details for PubMedCentralID PMC5992105